Arterial thrombosis of both native artery and bypass grafts in addition to pulmonary embolic disease have significant associated morbidity and mortality due to the disease process as well as the surgical and the non- surgical therapeutic treatments. Currently non surgical treatments employ thrombolytic intra-arterial or systemic agents such as Urokinase. These lytic agents are relatively safe but may have complications such as stroke, bleeding and dot embolization. Therapy may be protracted resulting in further ischemia and possible tissue loss. These procedures are often 48-72 hours long and require expensive intensive care monitoring. It is desirable to accelerate clot lysis thereby reducing the risks and costs associated with the procedure and minimizing morbidity. In this study we propose the use of intravascular ultrasound in conjunction with thrombolytic agent to increase the rate of thrombolysis. In-vivo experiments will be conducted to determine the best possible sonication conditions. Based on these results a catheter system that enables simultaneous delivery of ultrasound and thrombolytic agent will be designed and implemented. Using this system animal studies will be carried out to determine the effectiveness of the proposed technique. We believe that the use of ultrasound in combination with the thrombolytic agent may reduce the cost of treatment and also the morbidity associated with multitude vascular diseases involving arterial and aft thrombosis.

Agency
National Institute of Health (NIH)
Institute
National Heart, Lung, and Blood Institute (NHLBI)
Type
Research Project (R01)
Project #
5R01HL049517-02
Application #
2225587
Study Section
Surgery and Bioengineering Study Section (SB)
Project Start
1994-05-01
Project End
1997-04-30
Budget Start
1995-05-01
Budget End
1996-04-30
Support Year
2
Fiscal Year
1995
Total Cost
Indirect Cost
Name
University of Pennsylvania
Department
Radiation-Diagnostic/Oncology
Type
Schools of Medicine
DUNS #
042250712
City
Philadelphia
State
PA
Country
United States
Zip Code
19104
Blank, M; Eldor, A; Tavor, S et al. (1999) A mouse model for heparin-induced thrombocytopenia. Semin Hematol 36:12-6
Blank, M; Cines, D B; Arepally, G et al. (1997) Pathogenicity of human anti-platelet factor 4 (PF4)/heparin in vivo: generation of mouse anti-PF4/heparin and induction of thrombocytopenia by heparin. Clin Exp Immunol 108:333-9
Zhang, L; Strickland, D K; Cines, D B et al. (1997) Regulation of single chain urokinase binding, internalization, and degradation by a plasminogen activator inhibitor 1-derived peptide. J Biol Chem 272:27053-7
Higazi, A A; Mazar, A; Wang, J et al. (1997) Soluble human urokinase receptor is composed of two active units. J Biol Chem 272:5348-53
McCrae, K R; Cines, D B (1997) Thrombotic microangiopathy during pregnancy. Semin Hematol 34:148-58
Higazi, A A; Lavi, E; Bdeir, K et al. (1997) Defensin stimulates the binding of lipoprotein (a) to human vascular endothelial and smooth muscle cells. Blood 89:4290-8
Higazi, A A; Upson, R H; Cohen, R L et al. (1996) Interaction of single-chain urokinase with its receptor induces the appearance and disappearance of binding epitopes within the resultant complex for other cell surface proteins. Blood 88:542-51
Shlansky-Goldberg, R D; Cines, D B; Sehgal, C M (1996) Catheter-delivered ultrasound potentiates in vitro thrombolysis. J Vasc Interv Radiol 7:313-20
Higazi, A A; Ganz, T; Kariko, K et al. (1996) Defensin modulates tissue-type plasminogen activator and plasminogen binding to fibrin and endothelial cells. J Biol Chem 271:17650-5
Cines, D B; McCrae, K R (1995) The antiphospholipid-protein syndrome. J Clin Immunol 15:86S-100S

Showing the most recent 10 out of 11 publications